MRNA · News · 20261112N

Product / Drug Pipeline Progress

Moderna, Inc. · 2026-11-12 · Importance 46 · Surprise 42

At its 2026 Analyst Day, Moderna highlighted intismeran autogene, its individualized cancer therapy developed with Merck, following positive Phase 3 results in adjuvant melanoma. The company described intismeran as a lead oncology opportunity and said it had commercial and manufacturing readiness plans for the therapy. Moderna also highlighted recent approvals for its influenza vaccines mFLUSIVA and mCOFLU. Separately, peer-reviewed real-world data compared mNEXSPIKE’s effectiveness in reducing severe COVID-19 and hospitalizations among older adults with other available options.

Key facts